Sumitomo Mitsui DS Asset Management Company Ltd Raises Holdings in Illumina, Inc. (NASDAQ:ILMN)

Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,073 shares of the life sciences company’s stock after acquiring an additional 239 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Illumina were worth $1,960,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Illumina in the 3rd quarter worth approximately $30,000. VisionPoint Advisory Group LLC lifted its stake in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in shares of Illumina in the 4th quarter valued at approximately $37,000. Gradient Investments LLC lifted its stake in shares of Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares during the period. Finally, North Star Investment Management Corp. lifted its stake in shares of Illumina by 183.0% in the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 194 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen cut Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a research note on Thursday, January 4th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Finally, Stephens reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $167.70.

Illumina Stock Down 1.3 %

ILMN stock opened at $122.87 on Thursday. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $228.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The stock’s fifty day moving average price is $132.44 and its 200-day moving average price is $127.54.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the business posted $0.14 EPS. Equities analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Activity at Illumina

In related news, CEO Jacob Thaysen bought 7,330 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.17% of the stock is owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.